The World Awards Judges has been handpicked for their longstanding familiarity and deep knowledge of the ADC field. With a combined 85 years of development expertise they’ve occupied key leadership positions at the majority of the leading ADC companies.

 

 

 

Jagath Junutula, VP, Cellerant Therapeutics

Jagath Reddy Junutula, PhD joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs.  He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University. Jagath has authored 60 peer-reviewed publications/patents and has presented his work at numerous international conferences. Jagath serves as an editorial board member of leading antibody therapeutics journal, mAbs.

 

 

 Greg Landes, Independent Consultant, DNA Bridges

Gregory Landes has over 30 years of experience in the bio-technology industry with broad expertise in target discovery and validation, antibody and ADC drug discovery and preclinical development, molecular biology, genetics, genomics, and biochemistry. He currently consults with over a dozen companies in the disciplines described above as well as automation, biosimilars and antibody effector function. In addition, he leads workshops at national antibody conferences in a variety of areas of expertise including antibody effector function and antibody drug conjugates. He has held positions of significant responsibility with major biopharmaceutical companies including Takeda California/Takeda San Francisco (VP Biology/VP Discovery, Research and Preclinical Development, Lexicon Pharmaceuticals (VP, Biotherapeutics), Abgenix (VP, Product Discovery), Genzyme (VP, Genetics and Genomics), and Integrated Genetics ((Senior Scientist, Genetics and DNA Diagnostics). He holds a BA in Chemistry and PhD in Biochemistry from the University of Kansas and was awarded a post-doctoral scholarship from UCLA’s Molecular Biology Institute as well as an NIH post-doctoral award.

 

Pamela Trail, VP, Regeneron

Pamela Trail is Vice President of Oncology at Regeneron Pharmaceuticals. Dr.Trail has over 20 years of experience in the design and development of antibody drug conjugates as cancer therapeutics. Prior to joining Regeneron Dr. Trail served as Vice President of Oncology Research at MedImmune and held senior research positions at Seattle Genetics, Bayer, and Bristol-Myers Squibb. In those roles Dr. Trail contributed to the discovery and clinical development of multiple antibody drug conjugates, monoclonal antibodies, bispecific antibodies and small molecule cancer therapeutics. 


Walter Blättler, Independent Consultant

Walter Blättler graduated with a Dr. sc. nat. (Chemistry) from the Swiss Federal Institute of Technology, Zürich (ETH Zürich) and continued his education as a postdoctoral fellow in the Chemical Laboratories of Harvard University. He held research positions and was an Assistant Professor at Dana-Farber Cancer Institute, Harvard Medical School, before he started the research and development program at ImmunoGen, Inc. in Cambridge, MA, which he directed as Head of R&D for twenty years. ImmunoGen pioneered the development of antibody-drug conjugates for the treatment of cancer. From 2009 to 2011 he was director of pre-clinical development at Alfama Inc., which develops CO-releasing molecules (CO-RMs) for the treatment of various diseases. In 2011 he helped starting CoStim Pharmaceuticals as VP Development. CoStim Pharmaceuticals developed mAbs for immunotherapy of cancer and was bought by Novartis in 2014.